Riskpilot← Back to searchSign inGet full accessSSI Diagnostica A/S
A/SActiveCVR 37294535Herredsvejen 2Manufacture of pharmaceutical preparations · NACE 2120Est. 2015159 employees
Revenue 2025
DKK 320,2M
+34% vs 2024
EBITDA margin
1.9%
-84% vs 2024
Equity ratio
23.4%
Financial strength
Net profit 2025
DKK -107,4M
-86% vs 2024
| Revenue | DKK 320,2M | +34% |
| EBITDA | DKK 5,9M | -84% |
| Net profit | DKK -107,4M | -86% |
| Total assets | DKK 3B | +11% |
| Equity | DKK 695,8M | -45% |
| Employees | 159 | — |
Legal name
SSI Diagnostica A/S
CVR number
37294535
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
11. december 2015
Share capital
DKK 1.765.000
Employees
159 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem og en direktør i forening eller af to direktører i forening.
Company purpose
Selskabets formål er at drive virksomhed med udvikling, produktion og salg af in vitro diagnostika til mikrobiologisk diagnostik og kontrol samt hygiejnemonitorering i indland og udland, samt anden dermed beslægtet virksomhed.
Address
Herredsvejen 2
Phone
+4530523808
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 274.461 | 316.074 | 202.776 | 238.338 | 320.248 |
| Staff expenses | -57.502 | -0 | -53.849 | -83.794 | -104.478 |
| EBITDA | 216.819 | -4.952 | 53.532 | 37.659 | 5.943 |
| Depreciation & amort. | -16.774 | -0 | -28.650 | -17.267 | -47.588 |
| EBIT | 200.045 | -4.952 | 24.882 | 20.391 | -41.644 |
| Net financials | 90.618 | 31.413 | -132.998 | -81.992 | -77.156 |
| Profit before tax | 290.804 | 26.461 | -108.116 | -61.601 | -118.800 |
| Tax | 39.384 | -11.601 | 8.229 | -3.863 | -11.380 |
| Net profit | 251.420 | 38.062 | -126.826 | -57.738 | -107.420 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 999.322 | 3.185.375 | 2.722.933 | 2.672.997 | 2.976.120 |
| Equity | 690.076 | 1.016.146 | 1.247.705 | 1.270.028 | 695.791 |
| Long-term debt | 103.468 | 1.397.841 | 1.314.228 | 1.234.813 | 2.108.959 |
| Short-term debt | 178.941 | 756.250 | 132.170 | 139.326 | 153.832 |
| Total debt | 282.409 | 2.154.091 | 1.446.399 | 1.374.139 | 2.262.792 |
EBITDA margin
1.9%
This company
15.8%
Market median
-88% vs market
20212025
Equity ratio
23.4%
This company
38.2%
Market median
-39% vs market
20212025
Return on equity
-15.4%
This company
18.4%
Market median
-184% vs market
20212025
Net profit margin
-33.5%
This company
8.1%
Market median
-514% vs market
20212025
Asset turnover
0.11×
This company
1.12×
Market median
-90% vs market
20212025
Debt / equity
3.28×
This company
0.62×
Market median
-429% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
CC Chief Executive Officer | Chief Executive Officer | 2023 |
LH Management | Management | 2025 |
| Former (5) | ||
EM Management | Management | 2023 – 2024 |
HB Chief Executive Officer | Chief Executive Officer | 2015 – 2016 |
SS Management | Management | 2020 – 2023 |
SK Management | Management | 2016 – 2016 |
ES Management | Management | 2016 – 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2025 | |
| Board of Directors | 2016 | |
| Board of Directors | 2020 | |
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Former (9) | ||
| Board of Directors | 2015 – 2016 | |
| Chairman | 2016 – 2023 | |
| Board of Directors | 2020 – 2023 | |
| Board of Directors | 2016 – 2022 | |
| Chairman | 2016 – 2016 | |
| Board of Directors | 2022 – 2023 | |
| Chairman | 2016 – 2016 | |
| Chairman | 2015 – 2016 | |
| Board of Directors | 2016 – 2018 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SSI Diagnostica Holding A/S
SSI Diagnostica A/S Board members of SSI Diagnostica A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Egil Mølsted Madsen | Management | 0 companies |
| Helle Birk Krogsgaard | Chief Executive Officer | 0 companies |
| Christina Charlotte Lindved | Chief Executive Officer | 0 companies |
| Søren Skjold Mogensen | Management | 0 companies |
| Lars Henrik Vejrup Hansen | Management | 0 companies |
| Steffen Kjeld Thomsen | Management | 0 companies |
| Emil Staal Bergander | Management | 0 companies |
| Mie Lund Buhl | Board of Directors | 0 companies |
| Stig Løkke Pedersen | Chairman | 0 companies |
| Catherine Yaping Chen | Board of Directors | 0 companies |
| Bror Thomas Pollare | Board of Directors | 0 companies |
| Sibel Karina Arnes | Board of Directors | 0 companies |
| Joseph Edward Bernardo | Board of Directors | 0 companies |
| Jan Gunnar Åkesson | Chairman | 0 companies |
| Daniel Joseph Delaney | Board of Directors | 0 companies |
| Ole Jensen | Chairman | 0 companies |
| Rasmus Karl Gustaf Molander | Board of Directors | 0 companies |
| Nils Christian Strandberg Pedersen | Chairman | 0 companies |
| Sven Henrik Reinhold Geijer | Board of Directors | 0 companies |
| Patrik Olof Dahlén | Board of Directors | 0 companies |
| Ingo Sujit Michael Chakravarty | Board of Directors | 0 companies |
| Nachum Shamir | Chairman | 0 companies |